Cost-effectiveness analysis of tofacitinib compared with adalimumab and etanercept in the treatment of severe active rheumatoid arthritis; Iranian experience

Cost-Effectiveness Analysis of Certolizumab, Etanercept, Golimumab And Tofacitinib for The Treatment of Moderately To Severely Active Rheumatoid Arthritis

Value in Health ◽

10.1016/j.jval.2015.03.937 ◽

2015 ◽

Vol 18 (3) ◽

pp. A162

Author(s):

X. Han ◽

J.W. Hay

Keyword(s):

Rheumatoid Arthritis ◽

Cost Effectiveness ◽

Assessing the Value of Sarilumab Monotherapy for Adults with Moderately to Severely Active Rheumatoid Arthritis: A Cost-Effectiveness Analysis

Journal of Managed Care & Specialty Pharmacy ◽

10.18553/jmcp.2019.25.1.080 ◽

2019 ◽

Vol 25 (1) ◽

pp. 80-87 ◽

Cited By ~ 3

Author(s):

Melanie D. Whittington ◽

R. Brett McQueen ◽

Daniel A. Ollendorf ◽

Richard H. Chapman ◽

Varun M. Kumar ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Cost Effectiveness ◽

PMS29 CANADIAN COST-EFFECTIVENESS ANALYSIS OF ABATACEPT (ORENCIA™) FOR THE MANAGEMENT OF MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS IN PATIENTS WITH INADEQUATE RESPONSE TO METHOTREXATE

Value in Health ◽

10.1016/s1098-3015(10)72617-6 ◽

2010 ◽

Vol 13 (3) ◽

pp. A128

Author(s):

D Zou ◽

O Desjardins ◽

N Tsao ◽

R Goeree

Keyword(s):

Rheumatoid Arthritis ◽

Cost Effectiveness ◽

Inadequate Response ◽

PBI7 Cost-Effectiveness Analysis of Adalimumab Biosimilar Compared to Delayed Biologic Treatment Initiation in Patients with Rheumatoid Arthritis in Germany

Value in Health ◽

10.1016/j.jval.2021.04.078 ◽

2021 ◽

Vol 24 ◽

pp. S15

Author(s):

J. Porter ◽

P. Stuart ◽

R. Bartsch ◽

A. Lebioda

Keyword(s):

Rheumatoid Arthritis ◽

Cost Effectiveness ◽

Treatment Initiation ◽

Biologic Treatment ◽

PMS44 - COST-EFFECTIVENESS ANALYSIS OF SUBCUTANEOUS TOCILIZUMAB PLUS METHOTREXATE IN RHEUMATOID ARTHRITIS TREATMENT

Value in Health ◽

10.1016/j.jval.2018.09.1758 ◽

2018 ◽

Vol 21 ◽

pp. S295

Author(s):

E. Öksüz ◽

S. Malhan ◽

L. Yanik ◽

E. Koc ◽

E. Erdogan-Ciftci ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Cost Effectiveness ◽

Rheumatoid Arthritis Treatment ◽

PMS17 COST EFFECTIVENESS ANALYSIS OF UPADACITINIB AND METHOTREXATE FOR PATIENTS WITH METHOTREXATE-RESISTANT RHEUMATOID ARTHRITIS

Value in Health ◽

10.1016/j.jval.2020.04.704 ◽

2020 ◽

Vol 23 ◽

pp. S217

Author(s):

S. Jadhav ◽

Y. Yang

Keyword(s):

Rheumatoid Arthritis ◽

Cost Effectiveness ◽

Cost-Effectiveness Analysis Of Etanercept Versus Available Anti-Tnf And Il-6 Blockers For Treating Rheumatoid Arthritis In El Salvador

Value in Health ◽

10.1016/j.jval.2013.03.1138 ◽

2013 ◽

Vol 16 (3) ◽

pp. A224

Author(s):

M.A. Lutz ◽

R. Zelaya ◽

J.P. Bogantes ◽

G. Cuesta

Keyword(s):

Rheumatoid Arthritis ◽

Cost Effectiveness ◽

El Salvador ◽

PMS22 COST-EFFECTIVENESS ANALYSIS OF ETANERCEPT IN THE TREATMENT OF RHEUMATOID ARTHRITIS IN MEXICO

Value in Health ◽

10.1016/j.jval.2011.02.707 ◽

2011 ◽

Vol 14 (3) ◽

pp. A127

Author(s):

J. Vargas-Valencia ◽

M. Sotelo-Guzmán ◽

J.F. Mould-Quevedo ◽

E. Muciño-Ortega ◽

R.M. Galindo-Suarez

Keyword(s):

Rheumatoid Arthritis ◽

Cost Effectiveness ◽

Cost-Effectiveness Analysis Of Etanercept Versus Available Anti-Tnf And Il-6 Blockers For Treating Rheumatoid Arthritis In Costa Rica

Value in Health ◽

10.1016/j.jval.2013.03.1137 ◽

2013 ◽

Vol 16 (3) ◽

pp. A224

Author(s):

M.A. Lutz ◽

J.P. Bogantes ◽

G. Cuesta ◽

R. Saenz

Keyword(s):

Rheumatoid Arthritis ◽

Cost Effectiveness ◽

Costa Rica ◽

Sequences of biological treatments for patients with moderate-to-severe rheumatoid arthritis in the era of treat-to-target in China: a cost-effectiveness analysis

Clinical Rheumatology ◽

10.1007/s10067-021-05876-4 ◽

2021 ◽

Author(s):

Chongqing Tan ◽

Xia Luo ◽

Sini Li ◽

Lidan Yi ◽

Xiaohui Zeng ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Cost Effectiveness ◽

Treat To Target ◽

Severe Rheumatoid Arthritis ◽

Effectiveness Analysis ◽

Biological Treatments